Home Alzheimer’s Disease Dr. Scott Lipkin on Diversity in Clinical Trials at Miami Cancer Institute

Dr. Scott Lipkin on Diversity in Clinical Trials at Miami Cancer Institute

Clinical trial data is vital in determining treatment options for patients, and a diverse clinical trial population helps to accurately represent a city’s demographics. More than half of the Miami Cancer Institute’s clinical trial participants were Hispanic in 2019, setting the institution at the head of the curve for diversity.

While the idea of diversifying clinical trial populations is not widely practiced yet, the concept is not new. Scott Lipkin, DPM, CIP, chief research officer at Miami Cancer Institute, explained that the highest levels of the FDA have stressed the importance of clinical trial diversity to garner more accurate and effective results.

“When you think about clinical trials and clinical therapeutic research, we’re testing safety and efficacy of investigational drugs and devices to see if they can be brought to market because they offer a benefit that doesn’t…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments